Search research articles
Contact Us
Filters
Showing results (121-130 of 499) with videos related to
Page
of 50
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
November 3, 2012
Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin
István Láng, Claus-Henning Köhne, Gunnar Folprecht, et al.
Radiology and Oncology
|
March 8, 2017
Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results
Lawrence Bonne, Chris Verslype, Annouschka Laenen, et al.
Cancers
|
December 30, 2025
CA19-9 as a Dynamic Biomarker for Continuous Monitoring of Therapeutic Efficacy in Pancreatic Adenocarcinoma
Luigi Brancato, Damar Osok, Laurent Van den Bossche, et al.
International Journal of Dermatology
|
June 26, 2018
Scleroderma-like cutaneous lesions during treatment with paclitaxel and gemcitabine in a patient with pancreatic adenocarcinoma. Review of literature
Lien Verhulst, Esther Noë, Marie-Anne Morren, et al.
American Journal of Translational Research
|
March 23, 2019
Gemcitabine induces Epithelial-to-Mesenchymal Transition in patient-derived pancreatic ductal adenocarcinoma xenografts
Ashenafi Bulle, Jeroen Dekervel, Louis Libbrecht, et al.
Clinical Journal of Gastroenterology
|
April 12, 2021
A fatal wound complication following sequential anti-angiogenesis, immune checkpoint inhibition and ultra-hypofractionated radiotherapy
Miha Orazem, Cédric Draulans, Mathieu Spaas, et al.
Journal of Cancer Research and Clinical Oncology
|
May 15, 2023
Therapeutic yield of extensive molecular profiling in cholangiocarcinoma: a retrospective single-center study
Justine Vancanneyt, Bie Wilmsen, Caroline Luyten, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 16, 2009
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer
Hans Prenen, Jef De Schutter, Bart Jacobs, et al.
Cancer Treatment Reviews
|
March 25, 2014
Unmet needs and challenges in gastric cancer: the way forward
Florian Lordick, William Allum, Fátima Carneiro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 23, 2011
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies
Herbert I Hurwitz, Leonard B Saltz, Eric Van Cutsem, et al.
Page
of 50
Search research articles
Search
Showing results (121-130 of 499) with videos related to
Sort By:
Page
of 50
European Journal of Cancer (Oxford, England : 1990)
|
November 3, 2012
Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin
István Láng, Claus-Henning Köhne, Gunnar Folprecht, et al.
Radiology and Oncology
|
March 8, 2017
Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results
Lawrence Bonne, Chris Verslype, Annouschka Laenen, et al.
Cancers
|
December 30, 2025
CA19-9 as a Dynamic Biomarker for Continuous Monitoring of Therapeutic Efficacy in Pancreatic Adenocarcinoma
Luigi Brancato, Damar Osok, Laurent Van den Bossche, et al.
International Journal of Dermatology
|
June 26, 2018
Scleroderma-like cutaneous lesions during treatment with paclitaxel and gemcitabine in a patient with pancreatic adenocarcinoma. Review of literature
Lien Verhulst, Esther Noë, Marie-Anne Morren, et al.
American Journal of Translational Research
|
March 23, 2019
Gemcitabine induces Epithelial-to-Mesenchymal Transition in patient-derived pancreatic ductal adenocarcinoma xenografts
Ashenafi Bulle, Jeroen Dekervel, Louis Libbrecht, et al.
Clinical Journal of Gastroenterology
|
April 12, 2021
A fatal wound complication following sequential anti-angiogenesis, immune checkpoint inhibition and ultra-hypofractionated radiotherapy
Miha Orazem, Cédric Draulans, Mathieu Spaas, et al.
Journal of Cancer Research and Clinical Oncology
|
May 15, 2023
Therapeutic yield of extensive molecular profiling in cholangiocarcinoma: a retrospective single-center study
Justine Vancanneyt, Bie Wilmsen, Caroline Luyten, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 16, 2009
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer
Hans Prenen, Jef De Schutter, Bart Jacobs, et al.
Cancer Treatment Reviews
|
March 25, 2014
Unmet needs and challenges in gastric cancer: the way forward
Florian Lordick, William Allum, Fátima Carneiro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 23, 2011
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies
Herbert I Hurwitz, Leonard B Saltz, Eric Van Cutsem, et al.
Page
of 50